Showing results (21-30 of 51) with videos related to
Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 11, 2025
A Phase II Trial of Naxitamab plus Stepped-up Dosing of GM-CSF for Patients with High-Risk Neuroblastoma in First Complete RemissionBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.Cancer|April 3, 2014
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary eraBrian H Kushner, Shakeel Modak, Kim Kramer, et al.Military Medicine|February 21, 2012
Reticulocyte hemoglobin content testing for iron deficiency in healthy toddlersDevon Kuehn, Stephen S Roberts, Cara H Olsen, et al.Pediatric Blood & Cancer|July 2, 2020
Reduced-dose craniospinal irradiation for central nervous system relapsed neuroblastomaLeo Y Luo, Kim Kramer, Nai-Kong V Cheung, et al.International Journal of Cancer|September 22, 2016
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastomaBrian H Kushner, Nai-Kong V Cheung, Shakeel Modak, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2020
Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease ProgressionIrene Y Cheung, Nai-Kong V Cheung, Shakeel Modak, et al.Pediatric Blood & Cancer|May 20, 2022
Chemotherapy-induced thrombocytopenia in pediatric oncology: Scope of the problem and opportunities for interventionMelanie D Degliuomini, Katherine Armstrong, Audrey Mauguen, et al.International Journal of Radiation Oncology, Biology, Physics|February 15, 2019
Reduced-Dose Radiation Therapy to the Primary Site is Effective for High-Risk Neuroblastoma: Results From a Prospective TrialDana L Casey, Brian H Kushner, Nai-Kong V Cheung, et al.Cancer|March 3, 2015
Osteochondroma in long-term survivors of high-risk neuroblastomaBrian H Kushner, Stephen S Roberts, Danielle N Friedman, et al.Journal of Cancer Therapeutics & Research|December 19, 2014
PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastomaGiselle Saulnier Sholler, Erika A Currier, Akshita Dutta, et al.Pageof 6